News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
175,643 Results
Type
Article (7855)
Company Profile (23)
Press Release (167764)
Multimedia
Podcasts (15)
Webinars (2)
Section
Business (55968)
Career Advice (354)
Deals (9867)
Drug Delivery (26)
Drug Development (22422)
Employer Resources (32)
FDA (3673)
Job Trends (3954)
News (89071)
Policy (6349)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
Academia (512)
Accelerated approval (16)
ADA (18)
Adcomms (10)
Allergies (55)
Alliances (5807)
ALS (59)
Alzheimer's disease (439)
Antibody-drug conjugate (ADC) (167)
Approvals (3939)
Artificial intelligence (104)
ASCO (193)
Autoimmune disease (114)
Automation (13)
Bankruptcy (70)
Best Places to Work (3550)
BIOSECURE Act (4)
Biosimilars (57)
Biotechnology (16)
Bladder cancer (102)
Brain cancer (27)
Breast cancer (351)
Cancer (2406)
Cardiovascular disease (230)
Career advice (294)
Career pathing (3)
CAR-T (94)
CDC (9)
Celiac Disease (1)
Cell therapy (268)
Cervical cancer (23)
Clinical research (21178)
Collaboration (354)
Company closure (2)
Compensation (215)
Complete response letters (17)
COVID-19 (583)
CRISPR (76)
C-suite (118)
Cystic fibrosis (34)
Data (3709)
Depression (52)
Dermatology (46)
Diabetes (236)
Diagnostics (1689)
Digital health (11)
Diversity (3)
Diversity, equity & inclusion (12)
Drug discovery (64)
Drug pricing (27)
Drug shortages (4)
Duchenne muscular dystrophy (86)
Earnings (48358)
Editorial (14)
Employer branding (5)
Employer resources (26)
Events (35709)
Executive appointments (90)
FDA (4945)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (285)
Gene editing (141)
Generative AI (7)
Gene therapy (248)
GLP-1 (395)
Government (938)
Grass and pollen (1)
Guidances (340)
Healthcare (4865)
Hematology (66)
HIV (32)
Huntington's disease (21)
IgA nephropathy (58)
Immunology and inflammation (89)
Immuno-oncology (36)
Indications (77)
Infectious disease (686)
Inflammatory bowel disease (65)
Inflation Reduction Act (2)
Influenza (43)
Intellectual property (48)
Interviews (69)
IPO (6182)
IRA (8)
Job creations (585)
Job search strategy (255)
JPM (7)
Kidney cancer (13)
Labor market (29)
Layoffs (166)
Leadership (4)
Legal (1183)
Liver cancer (35)
Longevity (4)
Lung cancer (356)
Lymphoma (249)
Machine learning (13)
Management (10)
Manufacturing (160)
MASH (88)
Medical device (3286)
Medtech (3327)
Mergers & acquisitions (4039)
Metabolic disorders (615)
mRNA (43)
Multiple sclerosis (78)
NASH (9)
Neurodegenerative disease (110)
Neuropsychiatric disorders (34)
Neuroscience (912)
NextGen: Class of 2026 (1325)
Non-profit (874)
Now hiring (16)
Obesity (291)
Opinion (46)
Ovarian cancer (76)
Pain (58)
Pancreatic cancer (111)
Parkinson's disease (114)
Partnered (5)
Patents (102)
Patient recruitment (149)
Peanut (16)
People (5267)
Pharmaceutical (6)
Pharmacy benefit managers (8)
Phase 1 (5533)
Phase 2 (8831)
Phase 3 (8626)
Pipeline (4474)
Policy (43)
Postmarket research (848)
Preclinical (1932)
Press Release (16)
Prostate cancer (108)
Psychedelics (13)
Radiopharmaceuticals (97)
Rare diseases (350)
Real estate (652)
Recruiting (8)
Regulatory (5675)
Reports (17)
Research institute (429)
Resumes & cover letters (52)
Rett syndrome (33)
RNA editing (7)
RSV (33)
Schizophrenia (64)
Series A (37)
Series B (24)
Sickle cell disease (60)
Special edition (9)
Spinal muscular atrophy (41)
Sponsored (9)
Startups (530)
State (1)
Stomach cancer (7)
Supply chain (24)
Tariffs (13)
The Weekly (15)
Vaccines (284)
Venture capital (23)
Weight loss (225)
Women's health (44)
Worklife (5)
Date
Today (1)
Last 7 days (121)
Last 30 days (796)
Last 365 days (10006)
2026 (4947)
2025 (10060)
2024 (11376)
2023 (12820)
2022 (15347)
2021 (15098)
2020 (13776)
2019 (10991)
2018 (8211)
2017 (8221)
2016 (7144)
2015 (8990)
2014 (6199)
2013 (4618)
2012 (5210)
2011 (5393)
2010 (4871)
Location
Africa (150)
Alabama (26)
Alaska (1)
Arizona (75)
Arkansas (1)
Asia (10872)
Australia (1570)
California (4357)
Canada (1217)
China (557)
Colorado (213)
Connecticut (173)
Delaware (193)
Europe (24528)
Florida (548)
Georgia (162)
Hawaii (1)
Idaho (8)
Illinois (327)
India (27)
Indiana (275)
Iowa (3)
Japan (233)
Kansas (39)
Kentucky (13)
Louisiana (25)
Maine (51)
Maryland (444)
Massachusetts (3211)
Michigan (79)
Minnesota (195)
Missouri (43)
Montana (8)
Nebraska (2)
Nevada (38)
New Hampshire (19)
New Jersey (1457)
New Mexico (2)
New York (1133)
North Carolina (490)
North Dakota (2)
Northern California (2318)
Ohio (104)
Oklahoma (5)
Oregon (3)
Pennsylvania (918)
Puerto Rico (7)
Rhode Island (8)
South America (251)
South Carolina (9)
Southern California (1674)
Tennessee (37)
Texas (671)
United States (15356)
Utah (109)
Virginia (57)
Washington D.C. (15)
Washington State (328)
West Virginia (1)
Wisconsin (32)
175,643 Results for "9".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RNA editing
Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B
For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.
June 3, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
IRLAB Participates at Aktiedagarna in Stockholm on June 9
June 3, 2026
·
1 min read
Press Releases
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
June 8, 2026
·
3 min read
Press Releases
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
June 4, 2026
·
6 min read
Press Releases
Arcus Biosciences Announces New Employment Inducement Grants - June 9, 2026
June 10, 2026
·
1 min read
Press Releases
Summit Therapeutics Announces Proposed Public Offering of Common Stock - June 9, 2026
June 10, 2026
·
5 min read
Press Releases
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
June 3, 2026
·
4 min read
Sickle cell disease
Fulcrum lays off 85% of staff after dropping asset, leaving 9 employees
After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door.
June 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
June 5, 2026
·
5 min read
1 of 17,565
Next
